<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04942652</url>
  </required_header>
  <id_info>
    <org_study_id>Itraconazole_pH</org_study_id>
    <nct_id>NCT04942652</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Effects of Food or Proton Pump Inhibitor on the Pharmacokinetics of Itraconazole in Healthy Volunteers</brief_title>
  <official_title>An Open-label, Three-period, One-sequence Crossover Clinical Trial to Evaluate the Effects of Food or Proton Pump Inhibitor on the Pharmacokinetics of Itraconazole in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the effects of food or proton pump inhibitor on the&#xD;
      pharmacokinetics of itraconazole in healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation criteria&#xD;
&#xD;
        -  Pharmacokinetic assessment with plasma concentrations of itraconazole and&#xD;
           hydroxy-itraconazole&#xD;
&#xD;
        -  Safety assessments with adverse event monitoring including subjective/objective&#xD;
           symptoms, physical examination, vital signs, and laboratory tests&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2021</start_date>
  <completion_date type="Actual">August 24, 2021</completion_date>
  <primary_completion_date type="Actual">August 6, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax of itraconazole</measure>
    <time_frame>Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetic parameters of itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of itraconazole</measure>
    <time_frame>Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetic parameters of itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of itraconazole</measure>
    <time_frame>Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetic parameters of itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of itraconazole</measure>
    <time_frame>Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetic parameters of itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of itraconazole</measure>
    <time_frame>Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetic parameters of itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CL/F of itraconazole</measure>
    <time_frame>Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetic parameters of itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vd/F of itraconazole</measure>
    <time_frame>Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetic parameters of itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax of hydroxy-itraconazole</measure>
    <time_frame>Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetic parameters of hydroxy-itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast of hydroxy-itraconazole</measure>
    <time_frame>Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetic parameters of hydroxy-itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUCinf of hydroxy-itraconazole</measure>
    <time_frame>Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetic parameters of hydroxy-itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax of hydroxy-itraconazole</measure>
    <time_frame>Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetic parameters of hydroxy-itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>t1/2 of hydroxy-itraconazole</measure>
    <time_frame>Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetic parameters of hydroxy-itraconazole</description>
  </primary_outcome>
  <primary_outcome>
    <measure>metabolic ratio of hydroxy-itraconazole</measure>
    <time_frame>Day 1/Day 8/Day 16 pre-dose (0 hour), 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 24, 48, 72 hour post-dose</time_frame>
    <description>Pharmacokinetic parameters of hydroxy-itraconazole</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Achlorhydria</condition>
  <arm_group>
    <arm_group_label>Itraconazole 200 mg under fasted condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral administration of itraconazole 200 mg under fasted condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Itraconazole 200 mg under fed condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single oral administration of itraconazole 200 mg under fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole 40 mg + Itraconazole 200 mg under fasted condition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of esomeprazole 40 mg once daily for 6 days and then a single oral administration of itraconazole 200 mg under fasted condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole 200 mg</intervention_name>
    <description>Itraconazole 100 mg capsule x 2</description>
    <arm_group_label>Esomeprazole 40 mg + Itraconazole 200 mg under fasted condition</arm_group_label>
    <arm_group_label>Itraconazole 200 mg under fasted condition</arm_group_label>
    <arm_group_label>Itraconazole 200 mg under fed condition</arm_group_label>
    <other_name>Sporanox capsule</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole 40 mg</intervention_name>
    <description>Esomeprazole 40 mg tablet x 1</description>
    <arm_group_label>Esomeprazole 40 mg + Itraconazole 200 mg under fasted condition</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult aged ≥ 19 years and ≤ 50 years at the time of screening&#xD;
&#xD;
          -  Body weight of ≥ 55.0 kg and ≤ 90.0 kg, with body mass index (BMI) of ≥ 19.0 kg/m2 and&#xD;
             ≤ 30.0 kg/m2 at the time of screening&#xD;
&#xD;
          -  A subject without any congenital or chronic disease, and has no medical examination&#xD;
             result as pathological symptoms or signs&#xD;
&#xD;
          -  A subject who listened to sufficient explanation and fully understood this study, and&#xD;
             voluntarily decided to participate and agreed in writing to comply with the&#xD;
             precautions&#xD;
&#xD;
          -  A subject determined eligible for this study by investigator based physical&#xD;
             examination, clinical laboratory tests, interview, etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A subject with clinically significant hepatobiliary (severe hepatic impairment, etc.),&#xD;
             renal (severe renal impairment, etc.), neurologic, immunologic, respiratory,&#xD;
             gastrointestinal, endocrine, blood•oncology, cardiovascular (heart failure, Torsades&#xD;
             de pointes, etc.), urinary, or, psychical diseases (except for simple dental past&#xD;
             history such as tartar, impacted tooth, or wisdom tooth) or a history&#xD;
&#xD;
          -  A subject who has hypersensitivity to the investigational products, drugs containing&#xD;
             the same class, or other drugs (penicillin and antibiotics, etc.), or a history of&#xD;
             clinically significant hypersensitivity&#xD;
&#xD;
          -  A subject with a history of gastrointestinal disorders (gastrointestinal ulcer,&#xD;
             gastritis, gastrospasm, gastroesophageal reflux disease, Crohn's disease, etc.) or&#xD;
             surgery (except for simple appendectomy and herniotomy) that may affect the safety and&#xD;
             pharmacokinetics of the investigational products&#xD;
&#xD;
          -  A subject with the following results in the screening test:&#xD;
&#xD;
               1. Blood AST (GOT), ALT (GPT): &gt; Normal range upper × 1.5&#xD;
&#xD;
               2. QTc interval: &gt; 450 ms&#xD;
&#xD;
               3. Positive serological test (syphilis test, hepatitis B test, hepatitis C test,&#xD;
                  human immunodeficiency virus (HIV) test)&#xD;
&#xD;
          -  A subject with systolic blood pressure &lt; 80 mmHg or &gt; 160 mmHg, or diastolic blood&#xD;
             pressure &lt; 50 mmHg or &gt; 100 mmHg when vital signs are measured in sitting position&#xD;
             after resting for at least 3 minutes&#xD;
&#xD;
          -  A subject with a history of drug abuse&#xD;
&#xD;
          -  A subject who administered any prescription drugs or herbal medicine within 2 weeks&#xD;
             prior to the expected date of the first dose, or any over-the-counter drug (OTC drug,&#xD;
             health functional food or vitamin within 1 week prior to the expected date of the&#xD;
             first dose (However, can participate in the study if otherwise decided eligible by the&#xD;
             investigator), or is expected to administer it&#xD;
&#xD;
          -  A subject who administered drugs that induce (such as barbitals) or inhibit (such as&#xD;
             clarithromycin) the drug metabolizing enzymes within 1 month prior to the expected&#xD;
             date of the first dose&#xD;
&#xD;
          -  A subject who participated in other clinical trial or bioequivalence study within 6&#xD;
             months prior to the expected date of the first dose&#xD;
&#xD;
          -  A subject who donated whole blood within 2 months or the component blood within 1&#xD;
             month prior to the expected date of the first dose, or received blood transfusion&#xD;
             within 1 month prior to the expected date of the first dose&#xD;
&#xD;
          -  A subject with persistent alcohol intake (&gt; 21 units/week, 1 unit = 10 g of pure&#xD;
             alcohol), or inability to abstain from drinking from 3 days before the expected date&#xD;
             of the first dose until the last discharge&#xD;
&#xD;
          -  A subject with inability to refrain from grapefruit-containing food from 3 days before&#xD;
             the expected date of the first dose until the last discharge&#xD;
&#xD;
          -  A subject with excessive caffeine intake (&gt; 5 units/day), or inability to refrain from&#xD;
             caffeine or caffeine-containing food from 3 days before the expected date of the first&#xD;
             dose until the last discharge&#xD;
&#xD;
          -  A subject with inability to use a medically acceptable double contraception or&#xD;
             contraception throughout the study and for at least 4 weeks after the last dose, and&#xD;
             with inability to agree to donate sperm until the period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SeungHwan Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 20, 2021</study_first_submitted>
  <study_first_submitted_qc>June 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>SeungHwan Lee</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Achlorhydria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

